Evidence map›Paper›PMID 41641897›Full record

Trial reportClinical pharmacology in drug development2026

Pharmacokinetic Comparability of ABP 654, a Biosimilar to Ustekinumab, Administered Either via Prefilled Syringe or Autoinjector in Healthy Adults: Results from a Randomized, Open-Label, Parallel-Group Study.

Vincent Chow, Peter J Winkle, Daniel T Mytych, Jia Cao, Carolina Barragan, Alexander Colbert, Shalini Gupta, Waldemar Radziszewski, Janet Franklin

Abstract readRandomized Controlled TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical pharmacology in drug development, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Vincent ChowAmgen Inc., Thousand Oaks, CA, USA.
Peter J WinkleAnaheim Clinical Trials, Anaheim, CA, USA.
Daniel T MytychAmgen Inc., Thousand Oaks, CA, USA.
Jia CaoAmgen Inc., Thousand Oaks, CA, USA.
Carolina BarraganAmgen Inc., Thousand Oaks, CA, USA.
Alexander ColbertAmgen Inc., Thousand Oaks, CA, USA.
Shalini GuptaAmgen Inc., Thousand Oaks, CA, USA.
Waldemar RadziszewskiAmgen Inc., Thousand Oaks, CA, USA.
Janet FranklinAmgen Inc., Thousand Oaks, CA, USA.

Funding

Amgen Inc., Thousand Oaks, CA
6 · The paper itself

Abstract

ABP 654, a biosimilar to ustekinumab reference product, is available in a prefilled syringe (PFS) for subcutaneous (SC) use. The ABP 654 autoinjector pen (AIP) has recently been developed with an aim to improve the injection experience for patients and caregivers. This study was designed to assess the similarity of pharmacokinetics (PK), safety, and immunogenicity of a 90-mg SC injection of ABP 654 administered via PFS or AIP in healthy volunteers. A total of 156 adults were randomized at a ratio of 1:1. PK bioequivalence was established between the PFS and AIP groups based on the 90% CIs of the geometric mean ratios for the primary PK endpoints of maximum observed serum concentration (C

Indexed as

Biosimilar PharmaceuticalsUstekinumabAdolescentAdultArea Under CurveFemaleHealthy VolunteersHumansInjections, SubcutaneousMaleMiddle AgedSyringesTherapeutic EquivalencyYoung AdultBiosimilar PharmaceuticalsUstekinumabautoinjectorbioequivalencebiosimilarpharmacokineticsustekinumab

Identifiers

PMID41641897
PMCPMC12875155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.